Standard BioTools Inc (NASDAQ:LAB) shares, rose in value, with the stock price down by -5.47% to the previous day’s close as strong demand from buyers drove the stock to $2.42.
Actively observing the price movement in the last trading, the stock closed the session at $2.56. Referring to stock’s 52-week performance, its high was $3.16, and the low was $1.46. On the whole, LAB has fluctuated by -10.37% over the past month.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LAB’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LAB currently trading nearly -10.40% and -6.98% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.21, while the 7-day volatility ratio is showing 4.81% which for the 30-day chart, stands at 5.77%. Furthermore, Standard BioTools Inc (LAB)’s beta value is 1.64, and its average true range (ATR) is 0.15.
A comparison of Standard BioTools Inc (LAB) with its peers suggests the former has fared considerably weaker in the market. LAB showed an intraday change of -5.47% in last session, and over the past year, it grew by 40.70%%.
Data on historical trading for Standard BioTools Inc (NASDAQ:LAB) indicates that the trading volumes over the past 3 months, they’ve averaged 2.05 million. According to company’s latest data on outstanding shares, there are 383.05 million shares outstanding.
Nearly 3.54% of Standard BioTools Inc’s shares belong to company insiders and institutional investors own 54.08% of the company’s shares. The stock has risen by 9.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LAB stock heading into the next quarter.
